Investors & Partnerships

Pax Neuroscience is commercializing MoodMark®, the first blood-based biomarker for depression. With foundational patents, strong clinical validation, and a clear regulatory roadmap, Pax has positioned itself to become a leader in precision psychiatry.

Break Point: Investment or Partnership for Rollout

Pax is pursuing investors and strategic partners to secure funding for independent commercialization or leverage proven market entry resources. Partnership targets include leading diagnostic, pharmaceutical and lab companies who will benefit from a diagnostic product that spans the depression market.